If you can spare a few minutes, please help us improve our website by completing this survey.
Illuminating the science behind an ongoing clinical trial, Professor Michael Yaffe and his clinical and biotech collaborators tell the story of how a synergistic drug combination discovered at the Koch Institute revived an all but forgotten drug class and shows great promise for combatting resistant tumors. Beth Israel Deaconess Medical Center’s David Einstein shares clinical perspectives from the trial, and Trovagene’s Mark Erlander talks about the Plk-1 inhibitor that proved crucial for the introduction of this combination into prostate cancer. Achieving more together than they ever could on their own, this dynamic team embodies the powerful synergy they are bringing to patients.
Michael B. Yaffe, MD, PhD
Director, MIT Center for Precision Cancer Medicine
David H. Koch Professor of Science
Professor of Biology and Biological Engineering
Jesse Patterson, PhD
Postdoctoral Fellow, Yaffe Lab, Koch Institute
David Einstein, MD
Medical Oncologist, Beth Israel Deaconess Medical Center
Instructor, Medicine, Harvard Medical School
Mark Erlander, PhD
Chief Scientific Officer, Trovagene Oncology